

Correction: A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study

In *PLoS Clinical Trials*, volume 1, issue 1, doi: 10.1371/journal.pctr.0010003:

The following competing interest was declared by the author on submission, but due to an error the text was not included in the published version of the article: “Sean Emery receives research support from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, GlaxoSmithKline, Merck Sharpe and Dohme, and Roche.”

This correction note may be found online at doi:10.1371/journal.pctr.0020023.

Published May 4, 2007.

Citation: (2007) Correction: A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-Vanguard study. *PLoS Clin Trials* 2(5): e23. doi:10.1371/journal.pctr.0020023